Related Experiment Videos
[Lipoprotein (a), a cardiovascular risk factor: importance of its determination in current clinical practice]
Insights
High levels of Lipoprotein (a) [Lp(a)] significantly increase the risk of atherosclerosis. Measuring Lp(a) is crucial for assessing cardiovascular and cerebrovascular disease risk, especially in high-risk patients.
Area of Science:
- Cardiovascular Biology
- Lipid Metabolism
- Thrombosis Research
Context:
- Lipoprotein (a) [Lp(a)] is an LDL-like particle with thrombogenic and atherogenic properties due to its apo-lipoprotein (a) component, which shares homology with plasminogen.
- Epidemiological evidence strongly links elevated plasma Lp(a) levels to increased risk of coronary, cerebral, and peripheral atherosclerosis.
Purpose:
- To review the existing literature on the relationship between Lipoprotein (a) and atherosclerosis.
- To highlight the clinical significance of Lp(a) measurement in cardiovascular risk assessment.
Summary:
- Multiple prospective studies confirm that high Lp(a) is a significant risk factor for atherosclerosis.
- Discrepancies in some studies are attributed to sample handling or patient medication.
- Lp(a) possesses both atherogenic and thrombogenic capacities, contributing to vascular disease development.
Impact:
- Measuring Lp(a) is essential for a more accurate evaluation of atherosclerotic vascular disease risk.
- This is particularly important for patients with hyper LDLemia, a history of early cardio- or cerebrovascular events, or a family history of atherosclerosis.
- Understanding Lp(a)'s role can lead to improved patient stratification and personalized preventive strategies.
Abstract:
Lipoprotein (a) [Lp(a)] is a LDL-like particle linked to an apo-lipoprotein (a) which has high sequence homology with plasminogen that gives Lp(a) thrombogenic properties in addition to atherogenic capacity. Many epidemiological studies have shown that a high plasma level of Lp(a) is a risk factor for coronary, cerebral and peripheral atherosclerosis. Out of thirteen prospective studies, ten have confirmed this result. The negative results from the three remaining studies were probably due to either inadequate storage of the samples or preventive drug treatment given to the patients during the studies. This review of the literature clearly demonstrates the relationship between Lp(a) and atherosclerosis and the need to measure Lp(a) in order to better evaluate the risk of atherosclerotic vascular disease especially in patients with a hyper LDLemia, an early cardio- or cerebrovascular disease or a family history of atherosclerosis.